Lazard Asset Management LLC Has $4.35 Million Stake in Cellebrite DI Ltd. (NASDAQ:CLBT)

Lazard Asset Management LLC lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 197,488 shares of the company’s stock after acquiring an additional 7,058 shares during the quarter. Lazard Asset Management LLC owned approximately 0.10% of Cellebrite DI worth $4,350,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Gen Wealth Partners Inc acquired a new stake in shares of Cellebrite DI during the 4th quarter valued at $85,000. NewEdge Advisors LLC boosted its holdings in shares of Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Cellebrite DI during the 4th quarter valued at $100,000. Polen Capital Management LLC bought a new position in Cellebrite DI during the 4th quarter worth $222,000. Finally, Victory Capital Management Inc. bought a new position in Cellebrite DI during the 4th quarter worth $234,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Lake Street Capital lifted their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Needham & Company LLC cut their target price on Cellebrite DI from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. cut their target price on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $22.43.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $17.27 on Friday. The company has a market capitalization of $4.14 billion, a price-to-earnings ratio of -12.42, a P/E/G ratio of 4.27 and a beta of 1.44. The business’s 50-day moving average is $19.02 and its 200-day moving average is $20.24. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.